Table 1.
Subject demographic and baseline characteristics by treatment. All dosed subjects are included
| ch-mAb7F9 |
|||||||
|---|---|---|---|---|---|---|---|
| Variable/ Category | Placebo N = 10 | 0.2 mg/kg N = 6 | 0.6 mg/kg N = 6 | 2 mg/kg N = 7a | 6 mg/kg N = 6 | 20 mg/kg N = 7 | All Subjects N = 42 |
| Sex | |||||||
| Male | 6 (60.0%) | 5 (83.3%) | 5 (83.3%) | 4 (57.1%) | 2 (33.3%) | 3 (42.9%) | 25 (59.5%) |
| Female | 4 (40.0%) | 1 (16.7%) | 1 (16.7%) | 3 (42.9%) | 4 (66.7%) | 4 (57.1%) | 17 (40.5%) |
| Race | |||||||
| White | 3 (30.0%) | 3 (50.0%) | 5 (83.3%) | 6 (85.7%) | 3 (50.0%) | 2 (28.6%) | 22 (52.4%) |
| Black/AA | 6 (60.0%) | 3 (50.0%) | 1 (16.7%) | 1 (14.3%) | 3 (50.0%) | 3 (42.9%) | 17 (40.5%) |
| Asian | 0 | 0 | 0 | 0 | 0 | 1 (14.3%) | 1 (2.4%) |
| NH/other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 1 (14.3%) | 1 (2.4%) |
| AI or Alaskan Native | 1 (10.0) | 0 | 0 | 0 | 0 | 0 | 1 (2.4%) |
| Ethnicity | |||||||
| Not Hispanic | 9 (90.0%) | 5 (83.3%) | 6 (100.0%) | 7 (100.0%) | 6 (100.0%) | 7 (100.0%) | 40 (95.2%) |
| Hispanic | 1 (10.0%) | 1 (16.7%) | 0 | 0 | 0 | 0 | 2 (4.8%) |
| Age (years) | |||||||
| Mean | 30 | 24 | 26 | 22 | 32 | 26 | 27 |
| SD | 10 | 3 | 6 | 4 | 12 | 7 | 8 |
| Range | 20–44 | 20–28 | 20–36 | 19–28 | 18–46 | 19–36 | 18–46 |
Notes: AA = African American; AI = American Indian; NH = Native Hawaiian; SD = standard deviation. aInfusion was stopped/interrupted for one subject due to an adverse event of infusion reaction, but the subject's characteristics are included in the 2 mg/kg group column and totals.